Solifenacin

Cognitive Disorder

Astellas Pharma IncSmall moleculePhase 4 / ApprovedDormant

B

58/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 43/ 100
Competitive Position: 89/ 100

Competitive context

132 Active assets in the Cognitive Disorder cohort.

Asset / Sponsor	Phase	Rating
Nicotine University of Southern California	Phase 2	BBB
Oxybutynin University of Alberta	Phase 4	BBB
Metformin Fudan University	Phase 4	BB
Levodopa Vanderbilt University Medical Center	Phase 4	BB
Rivastigmine VA Office of Research and Development	Phase 4	BB

View all 50 →

Same molecule, other indications

Solifenacin is also rated in:

overactive bladderDormant

B

Indicative · Phase 4

62 / 100

urinary bladder, atony ofDormant

B

Indicative · Phase 4

58 / 100

Parkinson diseaseDormant

CCC

Indicative · Phase 4

54 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.